Holen Sie sich die Stockscreener-App
47.38
0.43%
0.05
Schlusskurs vom Vortag:
$47.33
Offen:
$47
24-Stunden-Volumen:
84,576
Relative Volume:
0.17
Marktkapitalisierung:
$1.32B
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-7.7928
EPS:
-6.08
Netto-Cashflow:
$-121.61M
1W Leistung:
+4.06%
1M Leistung:
-5.00%
6M Leistung:
+76.06%
1J Leistung:
+185.84%
1-Tages-Spanne:
$46.50
$48.08
1-Wochen-Bereich:
$44.25
$48.53
52-Wochen-Spanne:
$12.21
$52.47
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Vergleichen Sie ANAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
47.50 | 1.31B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
ANAPTYBIO INC (NASDAQ:ANAB) Offers High-Growth Momentum and a Bullish Technical Setup - Chartmill
Understanding the Setup: (ANAB) and Scalable Risk - Stock Traders Daily
Treasury Yields: Will AnaptysBio Inc benefit from geopolitical trendsJuly 2025 Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Barclays Raises Price Target for AnaptysBio (ANAB) to $78.00 | A - GuruFocus
Did Big EPS, Revenue Jump and JPM Spotlight Just Shift AnaptysBio's (ANAB) Investment Narrative? - simplywall.st
ANAPTYSBIO INC (NASDAQ:ANAB) Shows Minervini Trend Template and High-Growth Momentum Alignment - Chartmill
AnaptysBio Shares Face Pressure Amid Insider Sale and Strategic Uncertainty - AD HOC NEWS
Market Leaders: Is AnaptysBio Inc stock a good dividend stock2025 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Anaptysbio director Marquet sells $530k in shares By Investing.com - Investing.com Nigeria
AnaptysBio (NASDAQ:ANAB) Director Magda Marquet Sells 11,000 Shares - MarketBeat
Anaptysbio director Marquet sells $530k in shares - Investing.com
ANAB Stock Price, Forecast & Analysis | ANAPTYSBIO INC (NASDAQ:ANAB) - Chartmill
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Breakout Zone: Can AnaptysBio Inc generate free cash flowWeekly Stock Analysis & Real-Time Volume Trigger Notifications - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Stock Price Down 7.3%Time to Sell? - MarketBeat
AnaptysBio Teases 2026 Split, JEMPERLI Royalty Upside and Key Clinical Catalysts at JPM Conf - MarketBeat
ANAB: Separation into two focused entities targets value creation, with major clinical and royalty catalysts ahead - TradingView — Track All Markets
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally - AOL.com
AnaptysBio (NASDAQ:ANAB) Stock Price Up 7.2%Time to Buy? - MarketBeat
AnaptysBio stock: UBS reiterates Buy rating amid ongoing GSK litigation By Investing.com - Investing.com Canada
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock By Investing.com - Investing.com Nigeria
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock - Investing.com Australia
What Investors Should Know About a $163K AnaptysBio Insider Sale - sharewise.com
Why AnaptysBio Inc. stock could rally in 2025GDP Growth & Free Safe Capital Growth Stock Tips - ulpravda.ru
Assessing AnaptysBio (ANAB) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - ET Pharma
Anaptysbio CEO Faga sells $638k in shares By Investing.com - Investing.com South Africa
Anaptysbio CEO Faga sells $638k in shares - Investing.com
Anaptysbio (ANAB) chief medical officer sells $163,191 in stock By Investing.com - Investing.com UK
Anaptysbio CLO Loumeau sells $98,809 in shares By Investing.com - Investing.com Nigeria
Anaptysbio CFO Mulroy sells $112k in shares By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) CFO Dennis Mulroy Sells 2,515 Shares - MarketBeat
Eric Loumeau Sells 2,210 Shares of AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
Paul Lizzul Sells 3,650 Shares of AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
Anaptysbio CLO Loumeau sells $98,809 in shares - Investing.com
The Technical Signals Behind (ANAB) That Institutions Follow - Stock Traders Daily
What AnaptysBio (ANAB)'s Royalty Spin-Off Plan Means For Shareholders - Sahm
AnaptysBio files motion to dismiss in Tesaro/GSK royalty dispute By Investing.com - Investing.com Nigeria
AnaptysBio (NASDAQ:ANAB) Shares Gap Down Following Insider Selling - MarketBeat
Is AnaptysBio Inc. stock positioned for digital transformationGrip and Outsole Review & HOKA model picks for your routine - Улправда
AnaptysBio (NASDAQ:ANAB) Upgraded at UBS Group - MarketBeat
AnaptysBio Moves to Toss GSK/Tesaro Repudiation Claim Over Jemperli Royalties - prismnews.com
Anaptysbio CFO Mulroy sells $86k in shares By Investing.com - Investing.com Canada
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anaptysbio Inc-Aktie (ANAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Marquet Magda | Director |
Jan 15 '26 |
Sale |
48.23 |
11,000 |
530,531 |
9,930 |
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):